2-Ethyl-5,7-dimethyl-3-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)imidazo(4,5-b)pyridine (BioDeep_00000180315)

   

human metabolite blood metabolite


代谢物信息卡片


5-{2-[4-({2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl}methyl)phenyl]phenyl}-2H-1,2,3,4-tetrazole

化学式: C24H23N7 (409.2014838)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)N=C(C=C2C)C
InChI: InChI=1S/C24H23N7/c1-4-21-26-22-15(2)13-16(3)25-24(22)31(21)14-17-9-11-18(12-10-17)19-7-5-6-8-20(19)23-27-29-30-28-23/h5-13H,4,14H2,1-3H3,(H,27,28,29,30)

描述信息

D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
D057911 - Angiotensin Receptor Antagonists

同义名列表

3 个代谢物同义名

5-{2-[4-({2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl}methyl)phenyl]phenyl}-2H-1,2,3,4-tetrazole; 5-{2-[4-({2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl}methyl)phenyl]phenyl}-2H-1,2,3,4-tetrazole; 2-Ethyl-5,7-dimethyl-3-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)imidazo(4,5-b)pyridine



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Nevin Oruc, Omer Ozutemiz, Deniz Nart, Gul Yuce, Handan A Celik, Tankut Ilter. Inhibition of renin-angiotensin system in experimental acute pancreatitis in rats: a new therapeutic target?. Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie. 2010 Jul; 62(4):353-60. doi: 10.1016/j.etp.2009.05.001. [PMID: 19525099]
  • L T Tran, K M MacLeod, J H McNeill. Endothelin-1 modulates angiotensin II in the development of hypertension in fructose-fed rats. Molecular and cellular biochemistry. 2009 May; 325(1-2):89-97. doi: 10.1007/s11010-008-0023-z. [PMID: 19139972]
  • Kaoru Iwata, Tetsuro Sohda, Makoto Irie, Yasuaki Takeyama, Akira Anan, Satoshi Shakado, Shotaro Sakisaka. Angiotensin II type 1 receptor antagonist improves the prognosis in rats displaying liver cirrhosis induced by a choline-deficient diet. Journal of gastrointestinal and liver diseases : JGLD. 2008 Mar; 17(1):21-5. doi: ". [PMID: 18392239]
  • Shea Gilliam-Davis, Valerie S Payne, Sherry O Kasper, Ellen N Tommasi, Michael E Robbins, Debra I Diz. Long-term AT1 receptor blockade improves metabolic function and provides renoprotection in Fischer-344 rats. American journal of physiology. Heart and circulatory physiology. 2007 Sep; 293(3):H1327-33. doi: 10.1152/ajpheart.00457.2007. [PMID: 17616746]
  • Eric P Cohen, Brian L Fish, Mukut Sharma, X Allen Li, John E Moulder. Role of the angiotensin II type-2 receptor in radiation nephropathy. Translational research : the journal of laboratory and clinical medicine. 2007 Aug; 150(2):106-15. doi: 10.1016/j.trsl.2007.03.004. [PMID: 17656330]
  • Fara Saez, M Teresa Castells, Adelina Zuasti, Francisco Salazar, Virginia Reverte, Analia Loria, F Javier Salazar. Sex differences in the renal changes elicited by angiotensin II blockade during the nephrogenic period. Hypertension (Dallas, Tex. : 1979). 2007 Jun; 49(6):1429-35. doi: 10.1161/hypertensionaha.107.087957. [PMID: 17404180]
  • Andrea Kramer, Mabel van den Hoven, Angelique Rops, Tessa Wijnhoven, Lambert van den Heuvel, Joost Lensen, Toin van Kuppevelt, Harry van Goor, Johan van der Vlag, Gerjan Navis, Jo H M Berden. Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. Journal of the American Society of Nephrology : JASN. 2006 Sep; 17(9):2513-20. doi: 10.1681/asn.2006020184. [PMID: 16899518]
  • Yu-Long Li, Xiao-Hong Xia, Hong Zheng, Lie Gao, Yi-Fan Li, Dongmei Liu, Kaushik P Patel, Wei Wang, Harold D Schultz. Angiotensin II enhances carotid body chemoreflex control of sympathetic outflow in chronic heart failure rabbits. Cardiovascular research. 2006 Jul; 71(1):129-38. doi: 10.1016/j.cardiores.2006.03.017. [PMID: 16650840]
  • Jaspreet Singh Jaggi, Surya V Seshan, Michael R McDevitt, George Sgouros, Elizabeth Hyjek, David A Scheinberg. Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. International journal of radiation oncology, biology, physics. 2006 Apr; 64(5):1503-12. doi: 10.1016/j.ijrobp.2005.11.036. [PMID: 16503385]
  • Zhong-Gao Xu, Tae-Hyun Yoo, Dong-Ryeol Ryu, Hyeong Cheon Park, Sung Kyu Ha, Dae Suk Han, Sharon G Adler, Rama Natarajan, Shin-Wook Kang. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli. Kidney international. 2005 Mar; 67(3):944-52. doi: 10.1111/j.1523-1755.2005.00158.x. [PMID: 15698433]
  • P A Marcel de Vries, Dick de Zeeuw, Paul E de Jong, Gerjan Navis. The abnormal renal vasodilator response to D1-like receptor stimulation in conscious SHR can be normalized by AT1 blockade. Journal of cardiovascular pharmacology. 2004 Nov; 44(5):571-6. doi: 10.1097/00005344-200411000-00009. [PMID: 15505494]
  • Christoph P R Klett, Dock Anderson, Myssara Sholook, Joey P Granger. Antisense oligodeoxynucleotides directed against a novel angiotensinogen mRNA-stabilizing protein reduce blood pressure in spontaneously hypertensive rats. American journal of physiology. Regulatory, integrative and comparative physiology. 2004 Sep; 287(3):R619-26. doi: 10.1152/ajpregu.00140.2004. [PMID: 15155278]
  • John E Moulder, Brian L Fish, Eric P Cohen. Impact of angiotensin II type 2 receptor blockade on experimental radiation nephropathy. Radiation research. 2004 Mar; 161(3):312-7. doi: 10.1667/rr3129. [PMID: 14982483]
  • Eun-Young Lee, Myung Sook Shim, Mi Jin Kim, Sae Yong Hong, Young Goo Shin, Choon Hee Chung. Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes. Experimental & molecular medicine. 2004 Feb; 36(1):65-70. doi: 10.1038/emm.2004.9. [PMID: 15031673]
  • John E Moulder, Brian L Fish, Kevin R Regner, Eric P Cohen. Angiotensin II blockade reduces radiation-induced proliferation in experimental radiation nephropathy. Radiation research. 2002 Apr; 157(4):393-401. doi: 10.1667/0033-7587(2002)157[0393:aibrri]2.0.co;2. [PMID: 11893241]
  • YiLin Ren, Jeffrey L Garvin, Oscar A Carretero. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension (Dallas, Tex. : 1979). 2002 Mar; 39(3):799-802. doi: 10.1161/hy0302.104673. [PMID: 11897767]
  • Hendrik Bos, Robert H Henning, Eric De Boer, Anton T M G Tiebosch, Paul E De Jong, Dick De Zeeuw, Gerjan Navis. Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis. Kidney international. 2002 Feb; 61(2):473-80. doi: 10.1046/j.1523-1755.2002.00154.x. [PMID: 11849387]
  • Nina Uhlenius, Aaro Miettinen, Olli Vuolteenaho, Ilkka Tikkanen. Renoprotective mechanisms of angiotensin II antagonism in experimental chronic renal failure. Kidney & blood pressure research. 2002; 25(2):71-9. doi: 10.1159/000063511. [PMID: 12077487]
  • A Molteni, J E Moulder, E P Cohen, B L Fish, J M Taylor, P A Veno, L F Wolfe, W F Ward. Prevention of radiation-induced nephropathy and fibrosis in a model of bone marrow transplant by an angiotensin II receptor blocker. Experimental biology and medicine (Maywood, N.J.). 2001 Dec; 226(11):1016-23. doi: 10.1177/153537020122601108. [PMID: 11743137]
  • N Uhlenius, O Vuolteenaho, I Tikkanen. Renin-angiotensin blockade improves renal cGMP production via non-AT(2)-receptor mediated mechanisms in hypertension-induced by chronic NOS inhibition in rat. Journal of the renin-angiotensin-aldosterone system : JRAAS. 2001 Dec; 2(4):233-9. doi: 10.3317/jraas.2001.037. [PMID: 11881129]
  • D A Scheuer, A G Bechtold. Glucocorticoids potentiate central actions of angiotensin to increase arterial pressure. American journal of physiology. Regulatory, integrative and comparative physiology. 2001 Jun; 280(6):R1719-26. doi: 10.1152/ajpregu.2001.280.6.r1719. [PMID: 11353676]
  • P K Datta, J E Moulder, B L Fish, E P Cohen, E A Lianos. Induction of heme oxygenase 1 in radiation nephropathy: role of angiotensin II. Radiation research. 2001 May; 155(5):734-9. doi: 10.1667/0033-7587(2001)155[0734:iohoir]2.0.co;2. [PMID: 11302771]
  • Ariela Benigni, Susanna Tomasoni, Elena Gagliardini, Carla Zoja, James A Grunkemeyer, Raghu Kalluri, Giuseppe Remuzzi. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. Journal of the American Society of Nephrology : JASN. 2001 May; 12(5):941-948. doi: 10.1681/asn.v125941. [PMID: 11316852]
  • R Sabra, N Zeinoun, L H Sharaf, R Ghali, G Beshara, H Serhal. Role of humoral mediators in, and influence of a liposomal formulation on, acute amphotericin B nephrotoxicity. Pharmacology & toxicology. 2001 Apr; 88(4):168-75. doi: 10.1034/j.1600-0773.2001.d01-99.x. [PMID: 11322173]
  • H Peng, O A Carretero, M E Alfie, J A Masura, N E Rhaleb. Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene. Hypertension (Dallas, Tex. : 1979). 2001 Mar; 37(3):974-80. doi: 10.1161/01.hyp.37.3.974. [PMID: 11244026]
  • D Patiag, X Qu, S Gray, I Idris, M Wilkes, J P Seale, R Donnelly. Possible interactions between angiotensin II and insulin: effects on glucose and lipid metabolism in vivo and in vitro. The Journal of endocrinology. 2000 Dec; 167(3):525-31. doi: 10.1677/joe.0.1670525. [PMID: 11115780]
  • S Nakamura, I Nakamura, L Ma, D E Vaughan, A B Fogo. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney international. 2000 Jul; 58(1):251-9. doi: 10.1046/j.1523-1755.2000.00160.x. [PMID: 10886570]
  • P K Datta, J E Moulder, B L Fish, E P Cohen, E A Lianos. TGF-beta 1 production in radiation nephropathy: role of angiotensin II. International journal of radiation biology. 1999 Apr; 75(4):473-9. doi: 10.1080/095530099140401. [PMID: 10331853]
  • T Kai, K Sugimura, S Shimada, A Kurooka, T Takenaka, K Ishikawa. Inhibitory effects of a subdepressor dose of L-158,809, an angiotensin II type 1 receptor antagonist, on cardiac hypertrophy and nephropathy via the activated human renin-angiotensin system in double transgenic mice with hypertension. Japanese circulation journal. 1998 Aug; 62(8):599-603. doi: 10.1253/jcj.62.599. [PMID: 9741738]
  • N Asano, T Ogura, Y Mimura, M Kishida, H Kataoka, F Otsuka, T Yamauchi, H Makino. Renal AT1 receptor: autoradiographic localization and quantification in rat. Research communications in molecular pathology and pharmacology. 1998 May; 100(2):161-70. doi: NULL. [PMID: 9667070]
  • J E Moulder, B L Fish, E P Cohen. Angiotensin II receptor antagonists in the treatment and prevention of radiation nephropathy. International journal of radiation biology. 1998 Apr; 73(4):415-21. doi: 10.1080/095530098142257. [PMID: 9587080]
  • L K Gillies, E S Werstiuk, R M Lee. Cross-over study comparing effects of treatment with an angiotensin converting enzyme inhibitor and an angiotensin II type 1 receptor antagonist on cardiovascular changes in hypertension. Journal of hypertension. 1998 Apr; 16(4):477-86. doi: 10.1097/00004872-199816040-00009. [PMID: 9797193]
  • C Zoja, X H Liu, M Abbate, D Corna, E L Schiffrin, G Remuzzi, A Benigni. Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy. Experimental nephrology. 1998 Mar; 6(2):121-31. doi: 10.1159/000020519. [PMID: 9567218]
  • J R Kaiser, B E Cox, T A Roy, C R Rosenfeld. Differential development of umbilical and systemic arteries. I. ANG II receptor subtype expression. The American journal of physiology. 1998 03; 274(3):R797-807. doi: 10.1152/ajpregu.1998.274.3.r797. [PMID: 9530248]
  • J E Moulder, B L Fish, E P Cohen. Radiation nephropathy is treatable with an angiotensin converting enzyme inhibitor or an angiotensin II type-1 (AT1) receptor antagonist. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1998 Mar; 46(3):307-15. doi: 10.1016/s0167-8140(97)00175-8. [PMID: 9572624]
  • R D Manning, L Hu. Cardiovascular-renal responses to long-term nitric oxide inhibition during angiotensin II-AT1 receptor inhibition. American journal of hypertension. 1998 Mar; 11(3 Pt 1):328-39. doi: 10.1016/s0895-7061(97)00418-4. [PMID: 9544874]
  • F Otsuka, T Yamauchi, T Ogura, M Takahashi, J Kageyama, H Makino. Renal c-fos expression induced by angiotensin II is enhanced in spontaneously hypertensive rats. Life sciences. 1998; 63(23):2089-95. doi: 10.1016/s0024-3205(99)80005-8. [PMID: 9839532]
  • L K Gillies, M Lu, H Wang, R M Lee. AT1 receptor antagonist treatment caused persistent arterial functional changes in young spontaneously hypertensive rats. Hypertension (Dallas, Tex. : 1979). 1997 Dec; 30(6):1471-8. doi: 10.1161/01.hyp.30.6.1471. [PMID: 9403569]
  • C Zoja, R Donadelli, D Corna, D Testa, D Facchinetti, R Maffi, E Luzzana, V Colosio, T Bertani, G Remuzzi. The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: evidence based on comparative studies with a receptor antagonist. American journal of kidney diseases : the official journal of the National Kidney Foundation. 1997 Feb; 29(2):254-64. doi: 10.1016/s0272-6386(97)90038-x. [PMID: 9016898]
  • M Yamamoto, M Fukui, I Shou, L N Wang, K Sekizuka, S Suzuki, I Shirato, Y Tomino. Effects of treatment with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (AIIRA) on renal function and glomerular injury in subtotal nephrectomized rats. Journal of clinical laboratory analysis. 1997; 11(1):53-62. doi: 10.1002/(sici)1098-2825(1997)11:1<53::aid-jcla9>3.0.co;2-l. [PMID: 9021525]
  • T Oikawa, M Freeman, W Lo, D E Vaughan, A Fogo. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney international. 1997 Jan; 51(1):164-72. doi: 10.1038/ki.1997.20. [PMID: 8995730]
  • K Urabe, Y Matsumura, H Nonaka, M Nishiura, K Maeda, S Morimoto. Role of endogenous angiotensin II in renal hemodynamic and excretory responses to L-arginine infusion. Biological & pharmaceutical bulletin. 1996 Sep; 19(9):1149-53. doi: 10.1248/bpb.19.1149. [PMID: 8889032]
  • J E Moulder, B L Fish, E P Cohen, S M Bonsib. Angiotensin II receptor antagonists in the prevention of radiation nephropathy. Radiation research. 1996 Jul; 146(1):106-10. doi: 10.2307/3579403. [PMID: 8677292]
  • P M Lear, L J Heller, J R Prohaska. Cardiac hypertrophy in copper-deficient rats is not attenuated by angiotensin II receptor antagonist L-158,809. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). 1996 Jul; 212(3):284-92. doi: 10.3181/00379727-212-44018. [PMID: 8677275]
  • T Oishi, T Ogura, T Yamauchi, K Harada, Z Ota. Effect of renin-angiotensin inhibition on glomerular injuries in DOCA-salt hypertensive rats. Regulatory peptides. 1996 Apr; 62(2-3):89-95. doi: 10.1016/0167-0115(95)00166-2. [PMID: 8795070]
  • W R Huckle, M D Drag, W R Acker, M Powers, R C McFall, D J Holder, T Fujita, I I Stabilito, D Kim, D L Ondeyka, N B Mantlo, R S Chang, C F Reilly, R S Schwartz, W J Greenlee, R G Johnson. Effects of subtype-selective and balanced angiotensin II receptor antagonists in a porcine coronary artery model of vascular restenosis. Circulation. 1996 Mar; 93(5):1009-19. doi: 10.1161/01.cir.93.5.1009. [PMID: 8598064]
  • J P van Kats, L M Sassen, A H Danser, M P Polak, L K Soei, F H Derkx, M A Schalekamp, P D Verdouw. Assessment of the role of the renin-angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren. British journal of pharmacology. 1996 Mar; 117(5):891-901. doi: 10.1111/j.1476-5381.1996.tb15277.x. [PMID: 8851507]
  • L Paul, J Muralidharan, H Benediktsson. Glomerulosclerosis in kidney transplants: pathophysiologic mechanisms. Transplantation proceedings. 1996 Feb; 28(1):480-1. doi: NULL. [PMID: 8644319]
  • J H Bauer, G P Reams. The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs. Archives of internal medicine. 1995 Jul; 155(13):1361-8. doi: NULL. [PMID: 7794084]
  • K D Mitchell, J J Mullins. ANG II dependence of tubuloglomerular feedback responsiveness in hypertensive ren-2 transgenic rats. The American journal of physiology. 1995 May; 268(5 Pt 2):F821-8. doi: 10.1152/ajprenal.1995.268.5.f821. [PMID: 7771510]
  • S Perlman, H T Schambye, R A Rivero, W J Greenlee, S A Hjorth, T W Schwartz. Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor. The Journal of biological chemistry. 1995 Jan; 270(4):1493-6. doi: 10.1074/jbc.270.4.1493. [PMID: 7829475]
  • R Tanaka, K Sugihara, A Tatematsu, A Fogo. Internephron heterogeneity of growth factors and sclerosis--modulation of platelet-derived growth factor by angiotensin II. Kidney international. 1995 Jan; 47(1):131-9. doi: 10.1038/ki.1995.15. [PMID: 7731138]
  • E P Peten, L J Striker, A Fogo, I Ichikawa, A Patel, G E Striker. The molecular basis of increased glomerulosclerosis after blockade of the renin angiotensin system in growth hormone transgenic mice. Molecular medicine (Cambridge, Mass.). 1994 Nov; 1(1):104-15. doi: 10.1007/bf03403536. [PMID: 8790606]
  • R E Gibson, H T Beauchamp, C Fioravanti, N Brenner, H D Burns. Receptor binding radiotracers for the angiotensin II receptor: radioiodinated [Sar1, Ile8]Angiotensin II. Nuclear medicine and biology. 1994 May; 21(4):593-600. doi: 10.1016/0969-8051(94)90024-8. [PMID: 9234316]
  • A E Colletti, P A Krieter. Disposition of the angiotensin II receptor antagonist L-158,809 in rats and rhesus monkeys. Drug metabolism and disposition: the biological fate of chemicals. 1994 Mar; 22(2):183-8. doi: . [PMID: 8013272]
  • V Kon, A Fogo, I Ichikawa. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney international. 1993 Sep; 44(3):545-50. doi: 10.1038/ki.1993.279. [PMID: 8231026]
  • P Dagenais, E Escher. Anti-angiotensin antibodies cross-reactive with nonpeptide angiotensin antagonists as angiotensin receptor model. Regulatory peptides. 1993 Mar; 44(2):239-47. doi: 10.1016/0167-0115(93)90248-7. [PMID: 8385792]
  • T B Chen, V J Lotti, R S Chang. Characterization of the binding of [3H]L-158,809: a new potent and selective nonpeptide angiotensin II receptor (AT1) antagonist radioligand. Molecular pharmacology. 1992 Dec; 42(6):1077-82. doi: NULL. [PMID: 1480133]
  • P K Siegl, R S Chang, N B Mantlo, P K Chakravarty, D L Ondeyka, W J Greenlee, A A Patchett, C S Sweet, V J Lotti. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. The Journal of pharmacology and experimental therapeutics. 1992 Jul; 262(1):139-44. doi: . [PMID: 1625193]
  • Y Kakinuma, T Kawamura, T Bills, T Yoshioka, I Ichikawa, A Fogo. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney international. 1992 Jul; 42(1):46-55. doi: 10.1038/ki.1992.259. [PMID: 1635354]